Drugs for cardiovascular risk reduction in the diabetic patient.

被引:5
作者
Bell D.S. [1 ]
机构
[1] University of Alabama, Birmingham School of Medicine, Department of Medicine, 1808 7th Avenue South, Room 802, Birmingham, 35294, AL
关键词
Metformin; Cardiac Event; Carvedilol; Free Fatty Acid Level; Insulin Resistance Syndrome;
D O I
10.1007/s11892-001-0025-7
中图分类号
学科分类号
摘要
The diabetic patient is at increased risk for cardiac events. Lowering hemoglobin A1c levels even within the normal range is associated with less cardiac risk. Oral agents for diabetes that reduce insulin resistance and its associated cardiac risk factors in addition to lowering glucose should be used. Energetic reduction of blood pressure with an emphasis on the use of angiotensin-converting enzyme inhibitors and beta blockers will further reduce cardiac risk. Reduction of low-density lipoprotein and triglyceride levels and elevation of high-density lipoprotein levels through judicious use of statins and other anti-lipid agents is essential and will lower the rate of cardiac events in the diabetic patients even more than in the nondiabetic patients. In addition, aspirin and folic acid supplementation should be utilized. Use of a multiple risk factor management strategy with these drugs will lower morbidity and mortality, improve quality of life, and save cost for the diabetic patient.
引用
收藏
页码:133 / 139
页数:6
相关论文
共 118 条
[1]  
Krolewski AS(1977)Mortality from cardiovascular disease among diabetics Diabetologia 13 345-350
[2]  
Czyzyk A(1985)Coronary artery disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors Diabetologia 28 590-596
[3]  
Janeczko D(1988)Microalbuminuria as a predictor of vascular disease in non-diabetic subjects Lancet 2 530-533
[4]  
Kopczynski J(1986)Patterns of coronary artery disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population Am Heart J 111 383-390
[5]  
Jensen T(1995)Insulin resistance: syndrome or tendency? Lancet 346 100-103
[6]  
Borch-Johnsen K(1999)Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 33 119-120
[7]  
Kofoed-Enevoldsen A(1998)The optimal mode of coronary revascularization for diabetes: a risk adjusted long-term study comparing coronary angioplasty and coronary bypass surgery Eur Heart J 19 1696-1703
[8]  
Deckert T(1998)Advantages of alphaglucosidase inhibition as monotherapy in elderly type 2 diabetic patients J Clin Endocrinol Metab 83 1515-1522
[9]  
Yudkin JS(1999)Sulfonylureas and ischemic preconditioning, a double-blind placebo controlled evaluation of glimepiride and glibenclamide Eur Heart J 20 439-446
[10]  
Forrest RD(2000)Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405-412